CBMG
Phone: 400-832-5988
Main Products: Stem Cells
CBMG Biomedicine Group (NASDAQ: CBMG) was officially listed on NASDAQ in 2014, becoming the only Chinese cell therapy biotechnology company listed on NASDAQ. CBMG takes the lead in building an internationally leading diversified cell therapy biomedical product research and development platform with keen industry perception, precise judgment and strong R&D capabilities, and develops immune cell therapy products for cancer treatment and stem cells for the treatment of degenerative diseases Treatment products.
The tumor immune cell therapy platform covers chimeric antigen receptor T cell technology (CAR-T), tumor therapeutic vaccine technology (GVAX vaccine Dendrissim?), and is used to develop treatments for acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, and Hodge Cell therapy products for solid tumors such as gold lymphoma and advanced lung cancer. CBMG and the Chinese People’s Liberation Army General Hospital (301 Hospital) have cooperated in clinical research on chimeric receptor T cells (CAR-T) in the treatment of hematoma and solid tumors. The results of multiple clinical studies have attracted great attention from the international academic community. China has become one of the international leaders in tumor immunotherapy research. CBMG has initiated a phase I clinical study of CAR-T technology targeting CD19 for the treatment of refractory diffuse large B-cell lymphoma (DLBCL). This technology is optimized and improved on the basis of CBMGCAR-T patent CBM-C19.1, and is prepared in its own GMP production center base.
The stem cell platform covers the development of products for the treatment of knee osteoarthritis, cartilage injury and other degenerative diseases. Among them, the Phase II clinical study data of autologous adipose stem cell technology (ReJoin®) for the treatment of degenerative knee osteoarthritis has become a clinical result of successfully changing bone and joint diseases. The treatment of knee osteoarthritis with allogeneic adipose-derived mesenchymal stem cells (AlloJoinTM) has entered the phase I of clinical research. OTS)’s clinical trial is to develop and produce more mature and convenient stem cell products for the treatment of knee osteoarthritis.
CBMG has nearly 80 world-leading stem cell and immune cell technology patents (including authorized and pending), including 13 international patents and 10 PCT patents. CBMG’s chimeric antigen receptor (CART-CD20) technology for the treatment of malignant tumors has been patented by the Chinese Patent Office, becoming the first domestically patented CD20-targeted malignant tumor immune cell therapy technology.
CBMG has GMP production facilities in China that meet U.S. FDA standards and Chinese national standards. It is distributed in Shanghai, Beijing, and Wuxi. The total area exceeds 3000 square meters. It has 12 independent production lines. It is also one of the few international SGS facilities in China. A cell therapy technology company certified in accordance with the ISO9001 quality system, with clinical-grade, standardized cell preparation technology and supporting technologies, and has more than 1,000 standard management documents (SMP) and standard operating procedures (SOP). The company has cell banks in multiple cities, which can store more than 200,000 individual cells, and has the most advanced cold chain temperature control system (IT cloud system), which can monitor cell culture, storage and transportation.
Adhering to the concept of “saving lives and regenerating lives”, the company has gathered a large number of excellent stem cell and immunotherapy technical talents and management teams. Through the development and introduction of the world’s most advanced biological treatment technology, it has cooperated with large-scale research hospitals and scientific research institutions in the world Cooperation with scientific research and innovation platforms to build a solid translational medicine platform in an all-round way, and strive to become an internationally leading Chinese innovative cell biomedical technology company, providing the safest and most effective immunotherapy technologies and products for patients worldwide.